AKT1 and malignant colon neoplasm: UA is combined with the first-line chemotherapeutic drug Adriamycin, it can target and inhibit the AKT signaling pathway and activate the Hippo signaling pathway, reducing drug resistance, increasing apoptosis, inhibiting colon cancer (HCT 116) cell migration, and decreasing tumorigenesis [1069, 1070].